Accumulation of p53 in response to adenovirus early region 1A sensitizes human cells to tumor necrosis factor alpha-induced apoptosis

Many tumor cells are resistant to tumor necrosis factor alpha (TNFα)-induced apoptosis. Adenovirus early region 1A (AdE1A) sensitizes the otherwise resistant cells to TNFα. AdE1A also stabilizes the p53 protein. The present study demonstrates a correlation between AdE1A-induced sensitization and sta...

Full description

Saved in:
Bibliographic Details
Published in:Virology (New York, N.Y.) Vol. 340; no. 2; pp. 285 - 295
Main Authors: Zhang, Xian, Hussain, Rahel, Turnell, Andrew S., Mymryk, Joe S., Gallimore, Phillip H., Grand, Roger J.A.
Format: Journal Article
Language:English
Published: United States Elsevier Inc 30-09-2005
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Many tumor cells are resistant to tumor necrosis factor alpha (TNFα)-induced apoptosis. Adenovirus early region 1A (AdE1A) sensitizes the otherwise resistant cells to TNFα. AdE1A also stabilizes the p53 protein. The present study demonstrates a correlation between AdE1A-induced sensitization and stabilization of p53 in TNFα-induced apoptosis since the N-terminal and CR2 regions, the binding sites for CBP/p300, Rb and 26S proteasome regulatory components, are required for both these actions of AdE1A. TNFα does not induce apoptosis and AdE1A fails to sensitize TNFα cytotoxicity in p53-negative cells. However, introduction of exogenous p53 overcomes the cellular resistance to TNFα toxicity and enhances AdE1A sensitization, demonstrating that AdE1A sensitizes TNFα-induced apoptosis by its stabilization of p53. A proteasome inhibitor, lactacystin, enhances TNFα cytotoxicity in p53-positive and -negative cells, suggesting that accumulation of cellular proteins other than p53 might also regulate the cellular response to TNFα signaling.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0042-6822
1096-0341
DOI:10.1016/j.virol.2005.06.020